Germany talking to BioNTech about funding for vaccine capacity
Topics: GERMANY BIONTECH
The discussions follow a government “vaccine summit” this week with state leaders and representatives of pharmaceutical companies and the European Commission to discuss progress in vaccinating the population.
“At the Vaccine Summit, #BioNTech outlined a potential funding requirement of up to 400 million euros for reserving capacity and raw materials into next year. We are in exchange with the company to further firm this up,” Spahn tweeted.
“We are also talking to other #vaccine manufacturers about this,” he added. “We want to secure sufficient capacity for Germany, Europe and the world for 2022 in case of problematic mutations or necessary booster vaccinations.” ■